Destruxin B 黑僵菌素 B|cas:2503-26-6|西域试剂

Destruxin B 黑僵菌素 B,99.35%

产品编号：Bellancom-N6690| CAS NO：2503-26-6| 分子式：C₃₂H₅₅N₅O₇| 分子量：621.81

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-N6690		￥10500.00	杭州北京（现货）
Bellancom-N6690		￥27500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Destruxin B 黑僵菌素 B

产品介绍

Destruxin B 是从昆虫病原真菌中分离的绿僵菌 (Metarhizium anisopliae)，是一种具有杀虫和抗癌活性的环肽。 Destruxin B 通过 Bcl-2 家族依赖的线粒体途径在人类非小细胞肺癌细胞中诱导细胞凋亡。Destruxin B 显著激活 caspase-3，并在体外和体内通过 caspase 介导的细胞凋亡减少肿瘤细胞增殖。

生物活性

Destruxin B, isolated from entomopathogenic fungus Metarhizium anisopliae, is one of the cyclodepsipeptides with insecticidal and anticancer activities. Destruxin B induces apoptosis via a Bcl-2 Family-dependent mitochondrial pathway in human nonsmall cell lung cancer cells. Destruxin B significantly activates caspase-3 and reduces tumor cell proliferation through caspase-mediated apoptosis, not only in vitro but also in vivo.

体外研究

Destruxin B (1-30 μM; 48 hours) inhibits cell proliferation of H1299 cells and A549 cells, with IC₅₀s of 4.1 μM and 4.9 μM, respectively.
Activation of mitochondria-dependent caspase cascade plays an important role in Destruxin B (1-30 μM; 48 hours) induced apoptotic cell death in A549 cells.
Destruxin B (1.25-20.00 μM; 72 hours) treatment significantly inhibits HT-29 human colorectal cancer cells viability in time- and dose-dependent manners.
Destruxin B (10 or 20 μM; 12 and 24 hours) treatment markedly increases levels of the proapoptotic protein PUMA and reduces levels of antiapoptotic proteins Mcl-1 of A549 cells in a concentration- and time-dependent manner .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	H1299 cells
Concentration:	1, 5, 10, 20, 30 μM
Incubation Time:	48 hours
Result:	Inhibited H1299 cells proliferation of H1299 cells with an IC₅₀ of 4.1 μM.

Apoptosis Analysis

Cell Line:	Lung adenocarcinoma A549 cells
Concentration:	1, 5, 10, 20, 30 μM
Incubation Time:	48 hours
Result:	Induces caspase-dependent Lung adenocarcinoma A549 cells death.

Cell Viability Assay

Cell Line:	HT-29 human colorectal cancer cells
Concentration:	1.25, 2.50, 5.00, 10.00 and 20.00 μM
Incubation Time:	72 hours
Result:	The IC₅₀s at 24 h, 48 h and 72h were determined as 14.97, 2.00 and 0.67 μM, respectively.

Western Blot Analysis

Cell Line:	A549 cells
Concentration:	10 or 20 μM
Incubation Time:	12 and 24 hours
Result:	Regulates Mcl-1 and PUMA.

体内研究
(In Vivo)

Destruxin B (DB) ( injection; 0.6-15 mg/kg/day for 6 weeks) attenuates the tumor growth in time- and dose-dependent manners.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic female nude mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl), approximately 4-5 weeks old on arrival
Dosage:	Low dose (0.6 mg/kg), medium dose (3 mg/kg), high dose (15 mg/kg)
Administration:	Injection; daily; for 6 weeks
Result:	Low dose, medium dose and high dose indicated a reduction of 23.9%, 33.4% and 55.8% in mean tumor size, respectively.

体内研究

Destruxin B (DB) ( injection; 0.6-15 mg/kg/day for 6 weeks) attenuates the tumor growth in time- and dose-dependent manners.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic female nude mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl), approximately 4-5 weeks old on arrival
Dosage:	Low dose (0.6 mg/kg), medium dose (3 mg/kg), high dose (15 mg/kg)
Administration:	Injection; daily; for 6 weeks
Result:	Low dose, medium dose and high dose indicated a reduction of 23.9%, 33.4% and 55.8% in mean tumor size, respectively.

体内研究

Destruxin B (DB) ( injection; 0.6-15 mg/kg/day for 6 weeks) attenuates the tumor growth in time- and dose-dependent manners.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic female nude mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl), approximately 4-5 weeks old on arrival
Dosage:	Low dose (0.6 mg/kg), medium dose (3 mg/kg), high dose (15 mg/kg)
Administration:	Injection; daily; for 6 weeks
Result:	Low dose, medium dose and high dose indicated a reduction of 23.9%, 33.4% and 55.8% in mean tumor size, respectively.